Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
CodeBreaK 101 at ASCO 2025: Sotorasib Triplet in KRAS CRC
Joao Fogacci on Twitter: "RT @CathyEngMD: #ESMO22 Codebreak 101 update ...
邢镨元教授： CodeBreaK 100研究两年期随访结果公布——KRAS靶向药正在路上_患者_肿瘤_治疗
CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in ...
CodeBreaK 100/101 First report of safety and efficacy of sotorasib ...
CodeBreaK 101: Promising Safety and Efficacy of Sotorasib, Panitumumab ...
MA06.05 CodeBreaK 101: Safety and Efficacy of Sotorasib with ...
(PDF) CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC ...
CodeBreaK 100 Clinical Trial | LUMAKRAS® (sotorasib)
CodeBreaK 100 Study Design | LUMAKRAS® (sotorasib)
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of ...
CodeBreaK 101: Promising Safety and Efficacy of Sotorasib, Panitu...
CodeBreaK 200研究中期分析显示Sotorasib较化疗显著改善PFS与ORR|肿瘤|肺部疾病|生物学与医学|FDA|多西_新浪新闻
OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib ...
New Data From CodeBreaK Clinical Trial Demonstrate Efficacy of ...
Complete Overview of Codebreak 100 Sotorasib: Benefits and Uses
既治療のKRAS G12C変異大腸がんに対するソトラシブ＋パニツムマブ＋FOLFIRIの安全性と有効性（CodeBreaK 101 ...
CodeBreaK 200：Sotorasib治疗经治KRAS G12C 突变晚期 NSCLC的III 期试验 - 非小细胞肺癌 - 阳光肺科
Sotorasib + Panitumumab in KRAS G12C CodeBreak 300 Phase 3 Trial ...
CodeBreak 100: assessing sotorasib in patients with KRAS p.G12C-mutant ...
CodeBreaK 200: Sotorasib Offers Improved Quality of Life for Patients ...
CodeBreaK 200 & Sotorasib - by Timothée Olivier
CodeBreaK 300 Study Design | LUMAKRAS® (sotorasib) + Vectibix ...
CodeBreaK 101: preliminary results show promise of KRAS G12C inhibitor ...
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel ...
CodeBreaK 200研究中期分析显示Sotorasib较化疗显著改善PFS与ORR|抗癌|多西|突变_新浪新闻
CodeBreak 100: Phase I study of AMG 510, a novel KRAS G12C inhibitor ...
Promising Results from CodeBreaK 300 in KRAS G12C CRC
2023 ESMO | CodeBreaK 300研究更新：Sotorasib能否绝处逢生？ - 知乎
CodeBreak 300: sotorasib + panitumumab vs. standard-of-care in ...
CodeBreaK 200：Sotorasib治疗经治KRAS G12C 突变晚期 NSCLC的III 期试验 - 🥑非小细胞肺癌 - 阳光肺科
WCLC 2022丨常建华教授点评CodeBreaK 100/101：KRAS G12C抑制剂与PD-(L)1抑制剂联合能否突围医药新闻 ...
Sotorasib has broken the enigmatic code of KRAS G12C+ NSCLC | LCTT
从靶向治疗耐药机制到联合用药策略（下篇） | 熊言熊语
Sotorasib for previously treated colorectal cancers with KRASG12C ...
索托拉西布(Sotorasib) +帕尼单抗治疗G12C突变化疗难治性转移性结直肠癌：显著延长患者PFS，提高反应率 - 知乎
KRAS inhibitor sotorasib may become the new standard for advanced NSCLC ...
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated ...
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer | New ...
Amgen to Initiate Phase 3 Study of Sotorasib for NSCLC, Based on ...
JSMO 2023: Sotorasib versus Docetaxel for Previously Treated Non-Small ...
(PDF) 444TiP Trial in progress: A phase Ib study of sotorasib, a ...
Sotorasib versus docetaxel for previously treated non-small-cell lung ...
Data Look Promising for First-line Sotorasib, Platinum-based ...
UCSF Solid Tumor Trial → Sotorasib Activity in Subjects With Advanced ...
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer | NEJM
Sotorasib (Lumakras): Uses in Cancer: Side effects: Dosage: Expectation ...
Sotorasib-Sotorasib中文说明书,价格,哪里有卖-香港济民药业
A phase 1b study of sotorasib, a specific and irreversible KRASG12C ...
Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S ...
KRAS G12C変異を有する既治療切除不能大腸癌に対するSotorasib＋Panitumumab＋FOLFIRI併用療法の長期安全性および ...
Metastatic NSCLC Treatment Efficacy | LUMAKRAS™ (sotorasib)
A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed ...
505O Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line ...
FDA Pushes Back Decision on Sotorasib/Panitumumab in Colorectal Cancer ...
Sotorasib - wikidoc
Highlights on sotorasib plus panitumumab in KRAS G12C-mutated mCRC: The ...
ESMO 精读系列｜NCCN指南推荐！KRAS G12C突变型晚期结直肠癌的治疗进展 - 知乎
Sotorasib Plus Panitumumab Significantly Improves Outcomes in ...
Sotorasib for KRAS G12C–mutated non–small-cell lung cancer
Sotorasib (Lumakras)
FDA approved sotorasib with panitumumab for KRAS G12C-mutated ...
Sotorasib Shows Early Activity Against KRAS G12C Mutant NSCLC - ILCN ...
索托拉西布Sotorasib治疗KRAS G12C突变癌症的安全性和疗效-康安途海外医疗
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C ...
Sotorasib shows activity in KRAS G12C-mutated pancreatic cancer
FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC ...
Further Analyses Expand Upon Duration of Benefit With Sotorasib in KRAS ...
AMG-510战绩斐然！继打破不可成药，联合用药续写传奇！ - 知乎
The fate of sotorasib: a regulatory failure potentially harming ...
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in ...
安进公布KRAS G12C抑制剂Lumakras (sotorasib)联合用药研究新数据-上市-医保-临床适应症-香港济民药业
Superior PFS With Sotorasib in Colorectal Cancer | www.PhysiciansWeekly.com
CCRm KRAS G12C: FDA aprobó sotorasib junto con panitumumab, estudio ...
Sotorasib vs. Docetaxel for Previously Treated NSCLC With KRAS G12C ...
LUMAKRAS(SOTORASIB)与化疗的突破性联合治疗在KRAS G12C NSCLC中的前景 | 香港致泰药业
Sotorasib delays progression of advanced KRAS -mutant non-small cell ...
索托拉西布（sotorasib，amg510）联合曲美替尼（trametinib）治疗KRAS G12C突变实体瘤患者效果如何？ - 知乎
Lumakras (sotorasib) / Amgen, Carmot Therapeutics
【爱肠学院】CodeBreaK 300研究：Sotorasib+帕尼单抗在化疗难治性KRAS G12C突变型转移性结直肠癌的探索医药新闻 ...
Codebreak300: Sotorasib Plus Panitumumab in KRAS G12C-Mutated ...
amgen-announces-phase-iii-study-data-for-kras-g12c-inhibitor-sotorasib
Sotorasib improves PFS in KRAS G12C-mutated NSCLC
Combinação de sotorasibe e panitumumabe em câncer colorretal avançado ...
The FDA Approves Sotorasib With Panitumumab for Treatment of Patients ...
00605-7/asset/7feb7686-6f3e-4ccc-b108-07e7923109d4/main.assets/gr2.gif)
00605-7/asset/75d0e43e-b6b8-45ef-82a7-b5dabfa7da57/main.assets/gr1.gif)
00616-2/asset/ea3ab230-b179-4c20-a0eb-8a7b0d8c0a0e/main.assets/gr1_lrg.jpg)
